[House Report 106-975]
[From the U.S. Government Publishing Office]
106th Congress Report
HOUSE OF REPRESENTATIVES
2d Session 106-975
======================================================================
PROVIDING FOR CONSIDERATION OF A MOTION TO CONCUR IN THE SENATE
AMENDMENT WITH AN AMENDMENT TO H.R. 4386, THE BREAST AND CERVICAL
CANCER PREVENTION AND TREATMENT ACT OF 2000
_______
October 11, 2000.--Referred to the House Calendar and ordered to be
printed
_______
Mrs. Myrick, from the Committee on Rules, submitted the following
R E P O R T
[To accompany H. Res. 628]
The Committee on Rules, having had under consideration
House Resolution 628, by a nonrecord vote, report the same to
the House with the recommendation that the resolution be
adopted.
summary of provisions of resolution
The resolution provides for consideration in the House of a
motion to concur in the Senate amendment to H.R. 4386, the
Breast and Cervical Cancer Prevention and Treatment Act of
2000, with an amendment. The rule waives all points of order
against the motion. The rule provides one hour of debate on the
motion equally divided and controlled by the chairman and
ranking minority member of the Committee on Commerce. Finally,
the rule waives all points of order against the amendment
printed in this report.
Text of amendment made in order under the rule:
Add at the end of the Senate amendment the following section:
SEC. 3. HUMAN PAPILLOMAVIRUS; ACTIVITIES OF CENTERS FOR DISEASE CONTROL
AND PREVENTION.
Part B of title III of the Public Health Service Act (42
U.S.C. 243 et seq.) is amended by inserting before section 318
the following section:
``human papillomavirus
``Sec. 317P. (a) Surveillance.--
``(1) In general.--The Secretary, acting through the
Director of the Centers for Disease Control and
Prevention, shall--
``(A) enter into cooperative agreements with
States and other entities to conduct sentinel
surveillance or other special studies that
would determine the prevalence in various age
groups and populations of specific types of
human papillomavirus (referred to in this
section as `HPV') in different sites in various
regions of the United States, through
collection of special specimens for HPV using a
variety of laboratory-based testing and
diagnostic tools; and
``(B) develop and analyze data from the HPV
sentinel surveillance system described in
subparagraph (A).
``(2) Report.--The Secretary shall make a progress
report to the Congress with respect to paragraph (1)
not later than one year after the effective date of
this section.
``(b) Prevention Activities; Education Program.--
``(1) In general.--The Secretary, acting through the
Director of the Centers for Disease Control and
Prevention, shall conduct prevention research on HPV,
including--
``(A) behavioral and other research on the
impact of HPV-related diagnoses on individuals;
``(B) formative research to assist with the
development of educational messages and
information for the public, for patients, and
for their partners about HPV;
``(C) surveys of physician and public
knowledge, attitudes, and practices about
genital HPV infection; and
``(D) upon the completion of and based on the
findings under subparagraphs (A) through (C),
develop and disseminate educational materials
for the public and health care providers
regarding HPV and its impact and prevention.
``(2) Report; final proposal.--The Secretary shall
make a progress report to the Congress with respect to
paragraph (1) not later than one year after the
effective date of this section, and shall develop a
final proposal not later than two years after such
effective date, including a detailed summary of the
significant findings and problems and the best
strategies to prevent future infections.
``(c) HPV Education and Prevention.--
``(1) In general.--The Secretary shall prepare and
distribute educational materials for health care
providers and the public that include information on
all sexually transmitted diseases, including HPV and
HIV infection. Such materials shall address--
``(A) modes of transmission;
``(B) consequences of infection, including
the link between HPV and cervical cancer;
``(C) the effectiveness or lack of
effectiveness of both condoms and abstinence in
preventing infection with sexually transmitted
diseases, including HPV; and
``(D) the importance of regular pap smears,
HIV testing, and sexually-transmitted-disease
screening for early intervention purposes.
``(2) Medically accurate information.--Educational
materials under paragraph (1), and all other relevant
educational and prevention materials prepared for the
public and health care providers by the Secretary
(including materials prepared through the Food and Drug
Administration, the Centers for Disease Control and
Prevention, and the Health Resources and Services
Administration), or by other Federal departments or
agencies, or by contractors, grantees, or subgrantees
thereof, that are specifically designed to address
sexually transmitted diseases or condoms shall contain
medically accurate information regarding the
effectiveness or lack of effectiveness of condoms in
preventing HPV infection, HIV infection, and other
sexually transmitted diseases. Such requirement only
applies to materials mass produced for the public and
health care providers, and not to routine
communications.''.
SEC. 4. LABELING OF CONDOMS WITH RESPECT TO HUMAN PAPILLOMAVIRUS AND
OTHER SEXUALLY TRANSMITTED DISEASES.
The Secretary of Health and Human Services shall reexamine
existing condom labels that are authorized pursuant to the
Federal Food, Drug, and Cosmetic Act to ensure that the labels
are medically accurate and not misleading regarding the overall
effectiveness and lack of effectiveness of condoms in
preventing sexually transmitted diseases, including HIV
infection and infection with the human papillomavirus.